This was further validated using GBM cell lines and a patient-derived GBM xenograft cell line; it was observed that miR-31 targets TNF receptor-associated death domain (TRADD), thereby reducing NF-κB activation in GBM [174]. The gene discussed is NFKB1; the disease is glioblastoma.